An application made for this job — a tailored resume and cover letter that speak straight to the posting.
Genentech, a member of the Roche group and a leader in biotechnology, seeks a detail-oriented professional to manage the end-to-end Purchase Order lifecycle within gRED Contract Operations. You will influence spend forecasting and drive process optimization across global teams.
You will collaborate with global research, procurement, shared services, and finance, ensuring accurate cost center, WBS, and accounting code data to secure precise spend and accrual totals, while identifying
In this role, you will manage the end-to-end Purchase Order (PO) lifecycle for gRED Contract Operations, driving efficiency across our financial operations. You will join a dynamic, collaborative team where your insights will directly influence spend forecasting and process optimization.
You are a proactive, detail-oriented collaborator who thrives on optimizing processes and turning complex data into actionable insights. You enjoy working across boundary lines to build strong professional relationships and bring a continuous-learning mindset to your work.
Genentech is an equal opportunity employer. It is our policy and practice to employ, promote, and otherwise treat any and all employees and applicants on the basis of merit, qualifications, and competence. The company's policy prohibits unlawful discrimination, including but not limited to, discrimination on the basis of Protected Veteran status, individuals with disabilities status, and consistent with all federal, state, or local laws.
Genentech, a member of the Roche group and founder of the biotechnology industry, is dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. To solve the world's most complex health challenges, we ask bigger questions that challenge our industry and the boundaries of science to transform society. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. The next step is yours.